Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Pizzuti, Laura, Marchetti, Paolo, Natoli, Clara, Gamucci, Teresa, Santini, Daniele, Scinto, Angelo Fedele, Iezzi, Laura, Mentuccia, Lucia, D’Onofrio, Loretta, Botticelli, Andrea, Moscetti, Luca, Sperati, Francesca, Botti, Claudio, Ferranti, Francesca, Buglioni, Simonetta, Sanguineti, Giuseppe, Di Filippo, Simona, di Lauro, Luigi, Sergi, Domenico, Catenaro, Teresa, Tomao, Silverio, Giordano, Antonio, Maugeri-Saccà, Marcello, Barba, Maddalena, Vici, Patrizia
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://ncbi.nlm.nih.gov/pubmed/28878375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-10061-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars